Ian A Critchley
Overview
Explore the profile of Ian A Critchley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
993
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sewunet T, Razavi M, Rosenborg S, Camporeale A, Nowak M, Melnick D, et al.
Lancet Microbe
. 2024 Mar;
5(4):e355-e365.
PMID: 38432233
Background: Antimicrobials cause perturbations in the composition and diversity of the host microbiome. We aimed to compare gut microbiome perturbations caused by oral tebipenem pivoxil hydrobromide (a novel carbapenem) and...
2.
Cotroneo N, Stokes S, Pucci M, Rubio A, Hamed K, Critchley I
J Antimicrob Chemother
. 2024 Feb;
79(4):875-882.
PMID: 38394463
Background: Non-tuberculous mycobacterial pulmonary disease (NTM-PD) is increasing worldwide, with Mycobacterium avium complex (MAC) and Mycobacterium abscessus as the predominant pathogens. Current treatments are poorly tolerated and modestly effective, highlighting...
3.
Melnick D, Talley A, Gupta V, Critchley I, Eckburg P, Hamed K, et al.
Antimicrob Agents Chemother
. 2023 Sep;
67(10):e0053523.
PMID: 37768311
The clinical relevance of bacteriuria following antibiotic treatment of complicated urinary tract infections in clinical trials remains controversial. We evaluated the impact of urine pharmacokinetics on the timing of recurrent...
4.
Eckburg P, Muir L, Critchley I, Walpole S, Kwak H, Phelan A, et al.
N Engl J Med
. 2022 Apr;
386(14):1327-1338.
PMID: 35388666
Background: There is a need for oral antibiotic agents that are effective against multidrug-resistant gram-negative uropathogens. Tebipenem pivoxil hydrobromide is an orally bioavailable carbapenem with activity against uropathogenic Enterobacterales, including...
5.
Critchley I, Cotroneo N, Pucci M, Jain A, Mendes R
J Glob Antimicrob Resist
. 2020 Nov;
23:439-444.
PMID: 33212286
Objectives: Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis are urinary tract infection (UTI) pathogens and extended spectrum β-lactamase (ESBL)-producing pathogens exhibit co-resistance to oral fluoroquinolones (FQ) and trimethoprim-sulphamethoxazole (TMP-SMX). This...
6.
Cotroneo N, Rubio A, Critchley I, Pillar C, Pucci M
Antimicrob Agents Chemother
. 2020 May;
64(8).
PMID: 32423950
The continued evolution of bacterial resistance to the β-lactam class of antibiotics has necessitated countermeasures to ensure continued effectiveness in the treatment of infections caused by bacterial pathogens. One relatively...
7.
Critchley I, Cotroneo N, Pucci M, Mendes R
PLoS One
. 2019 Dec;
14(12):e0220265.
PMID: 31821338
Urinary tract infections (UTIs) caused by Escherichia coli have been historically managed with oral antibiotics including the cephalosporins, fluoroquinolones and trimethoprim-sulfamethoxazole. The use of these agents is being compromised by...
8.
Torres A, Rank D, Melnick D, Rekeda L, Chen X, Riccobene T, et al.
Open Forum Infect Dis
. 2019 May;
6(4):ofz149.
PMID: 31041348
Background: Hospital-acquired and ventilator-associated pneumonia (HAP/VAP; nosocomial pneumonia) due to Gram-negative pathogens are associated with significant morbidity and mortality; treatment options for multidrug-resistant infections are limited. The pivotal phase III...
9.
Das S, Li J, Riccobene T, Carrothers T, Newell P, Melnick D, et al.
Antimicrob Agents Chemother
. 2019 Jan;
63(4).
PMID: 30670413
Avibactam is a non-β-lactam β-lactamase inhibitor that has been approved in combination with ceftazidime for the treatment of complicated intra-abdominal infections, complicated urinary tract infections, and nosocomial pneumonia, including ventilator-associated...
10.
Nichols W, Stone G, Newell P, Broadhurst H, Wardman A, MacPherson M, et al.
Antimicrob Agents Chemother
. 2018 Aug;
62(11).
PMID: 30061279
Clinical susceptibility breakpoints against and for the ceftazidime-avibactam dosage regimen of 2,000/500 mg every 8 h (q8h) by 2-h intravenous infusion (adjusted for renal function) have been established by the...